Analyst/Sr. Analyst, Strategy & Operations, CMC & Supply Chain

You think in both experimental logic and business models, moving fluidly between them.

You've worked in a lab and understand how science and business intersect.

You thrive in data, building structured models and communicating cleanly through slides and narrative.

You learn fast, welcome feedback, and hold yourself to a standard of analytical and communication rigor that enables clear and informed decision-making for department and company leadership.

Passion for getting lifesaving medicines into the hands of patients quickly, efficiently, and compliantly

Relevant internships or co‑ops in management consulting, investment banking, equity research, or corporate role in a therapeutics company welcome.

Analyst, Strategy & Operations

, you will partner directly with the Director, Strategy & Operations, CMC and Supply Chain, to help shape how we make and deliver medicines.

You’ll work across functions that bridge science, operations, and business—turning data into insight and insight into action.

Your work spans strategic analyses, operational planning, and communications that keep leadership aligned to what matters most: supply continuity, cost, and speed.

One week you might be modeling COGS drivers or supporting a build-vs-buy assessment; the next you're synthesizing cross-functional inputs into a crisp update to leadership.

If you think in both scientific and business terms and get energy from seeing your analysis inform real decisions, you'll fit right in.

BridgeBio

is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. We bridge the gap between remarkable advancements in genetic science in academic institutions and the delivery of meaningful medicines to patients. Founded in 2015, the company has built a portfolio of 30+ drug development programs ranging from preclinical to late-stage development in multiple therapeutic areas including genetic dermatology, precision oncology, cardiology, endocrinology, neurology, pulmonology, and renal disease, with three approved drugs.

Our focus on scientific excellence and rapid execution aims to translate today’s discoveries into tomorrow’s medicines. We have U.S. offices in San Francisco; Palo Alto; Washington, D.C.; and Raleigh, with small satellites in other parts of the country. We also have international offices in Montreal, Canada, and Zurich, Switzerland, and are expanding across Europe.